STRO Sutro Biopharma
- 4.220
- +0.070+1.69%
Sutro Biopharma News
The Past Three Years for Sutro Biopharma (NASDAQ:STRO) Investors Has Not Been Profitable
BofA Starts Sutro at Buy, Cites Ovarian Cancer Drug Candidate
BofA Securities Starts Sutro Biopharma With Buy Rating
Sutro Biopharma (STRO) has an average rating of buy and price targets ranging from $8 to $20, according to analysts polled by Capital IQ. Price: 4.5200, Change: +0.27, Percent Change: +6.35
Sutro Biopharma Price Target Announced at $12.00/Share by B of A Securities
Sutro Biopharma Price Target Announced at $12.00/Share by B of A Securities
Sutro Biopharma Initiated at Buy by B of A Securities
Sutro Biopharma Initiated at Buy by B of A Securities
B of A Securities Initiates Coverage On Sutro Biopharma With Buy Rating, Announces Price Target of $12
B of A Securities analyst Tazeen Ahmad initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $12.
Even After Rising 15% This Past Week, Sutro Biopharma (NASDAQ:STRO) Shareholders Are Still Down 79% Over the Past Three Years
Sutro Biopharma, Inc. (NASDAQ:STRO) shareholders should be happy to see the share price up 15% in the last week. But that doesn't change the fact that the returns over the last three years have bee
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment –– Planned 50 patients in Dose-Optimization (Part
CVAC, SBNY and CRMD Are Among After Hour Movers
Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
Sutro Biopharma, Inc. (NASDAQ:STRO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased t
Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating
Sutro Biopharma (STRO) has an average buy rating and price target range of $8 to $20, according to analysts polled by Capital IQ. Price: 5.11, Change: +0.01, Percent Change: +0.29
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18
Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma with a Buy and lowers the price target from $25 to $18.
Sutro Biopharma Price Target Maintained With a $17.00/Share by JMP Securities
Sutro Biopharma Price Target Maintained With a $17.00/Share by JMP Securities
JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma with a Market Outperform and maintains $17 price target.
Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)
Sutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising Pipeline
Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
What's Going On With Sutro Biopharma (STRO) Stock?
Sutro Biopharma Inc (NASDAQ:STRO) shares are trading lower by 2.8% to $5.18 during Tuesday's session after the company announced the pricing of an underwritten offering of 14,478,764 shares of its com
Analysis
Price Target
No Data
